Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Nurse Phone Check-ins for People Finished With Cancer Treatment

Tests regular nurse phone calls for adults who finished breast, colorectal or prostate cancer treatment.

Plain-language title generated from the registry record
Registry title: Nurse-led Proactive Telephone Follow-up With Patients After Completion of Primary Cancer Treatment

Key facts

Where
Umeå, SwedenSee the site

Where in Sweden

  • Norrlands universitetssjukhusUmeå, SwedenNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Umeå University
Trial code
NCT06223022
Record updated
2 April 2025
Original description
The goal of this randomized study is to test and evaluate nurse-led telephone follow-up intervention in patients primarily curatively treated for breast cancer, colorectal cancer, and prostate cancer.Read full original descriptionShow less

How Are You Getting on? Nurse-led Proactive Telephone Follow-up With Patients After Completion of Primary Cancer Treatment Increases Their Sense of Security and Well-being

The goal of this randomized study is to test and evaluate nurse-led telephone follow-up intervention in patients primarily curatively treated for breast cancer, colorectal cancer, and prostate cancer.

The main question aims to answer:

Does this nurse-led telephone follow-up improve patients' quality of life? Participants in both groups will be asked to fill in questionnaires regularly. The intervention group will get a telephone follow-up at predetermined intervals, while the control group will get the care as usual.The investigators will compare intervention and control groups to see if predetermined regular nurse-led telephone follow-up improves quality of life.

Inclusion: Being primarily curatively treated for breast, colorectal-, or prostate cancer.

Exclusion: no cognitive impairment; no adjuvant treatment; no known alcohol or other misuse.

ClinicalTrials.gov NCT06223022